OpinionPublished 28 Feb 2025
Liquid Biopsies and ctDNA: Revolutionizing Diagnosis, Monitoring, and Personalized Treatment in Gynecologic Cancers
Department of Precision Diagnostics, Starlight Oncology Center, Boston, MA, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Liquid biopsies, particularly those analyzing circulating tumor DNA (ctDNA), have emerged as a non-invasive tool for diagnosis, monitoring, and treatment personalization in gynecologic cancers, including ovarian, endometrial, and cervical cancers. This article reviews the applications of liquid biopsies, focusing on their role in early detection, recurrence monitoring, and guiding targeted therapies. Clinical studies demonstrate 90% sensitivity for detecting recurrence, with ctDNA outperforming traditional biomarkers. Challenges include standardization and cost. Future directions involve integrating multi-omics and artificial intelligence to enhance clinical utility.
Keywords
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalInsights in Gynecologic Oncology
- SubjectOncology & Cancer
- SubjectReproductive Medicine & Gynaecology
- BylineArticles whose byline prints “Sophia N. Lee”